Skip to main content

NEW YORK (TheStreet) -- Sophiris Bio (SPHS) - Get Sophiris Bio Inc. Report stock is soaring by 15.18% to $3.34 on heavy trading volume Wednesday afternoon, after the company announced that its drug met the goal of a late-stage study.

The La Jolla, CA-based bio-pharmaceutical company announced yesterday that a Phase 3 trial for the prostate treatment met its primary endpoint.

Patients using the drug experienced significant relief of their symptoms, the company added. 

"We believe that a statistically significant improvement in International Prostate Symptom Score, if replicated in a second Phase 3 trial, may be sufficient for registration with the FDA," CEO Allison Hulme said in a statement yesterday.

A preliminary analysis by the company in December showed the treatment would not be effective, Reuters reported.

TheStreet Recommends

So far today, 10.11 million shares of Sophiris have traded, versus the company's 30-day average of 999,922 shares. 

Image placeholder title

SPHS

data by

YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.